Nymox Pharmaceutical Corp. (NYMXF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NYMXF Profit Margin, ROE & Profitability Analysis
NYMXF vs Healthcare Sector: How Nymox Pharmaceutical Corp. Compares
How Nymox Pharmaceutical Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nymox Pharmaceutical Corp. Stock Overvalued? NYMXF Valuation Analysis 2026
Based on fundamental analysis, Nymox Pharmaceutical Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nymox Pharmaceutical Corp. Balance Sheet: NYMXF Debt, Cash & Liquidity
NYMXF Revenue Growth, EPS Growth & YoY Performance
NYMXF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nymox Pharmaceutical Corp. (CIK: 0001018735)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NYMXF
What is the AI rating for NYMXF?
Nymox Pharmaceutical Corp. (NYMXF) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NYMXF's key strengths?
Claude: Analysis in progress.
What are the risks of investing in NYMXF?
Claude: Analysis in progress.
What is NYMXF's revenue and growth?
Nymox Pharmaceutical Corp. reported revenue of N/A.
Does NYMXF pay dividends?
Nymox Pharmaceutical Corp. does not currently pay dividends.
Where can I find NYMXF SEC filings?
Official SEC filings for Nymox Pharmaceutical Corp. (CIK: 0001018735) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NYMXF's EPS?
Nymox Pharmaceutical Corp. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NYMXF's fundamental grade?
Based on our AI fundamental analysis in July 2026, Nymox Pharmaceutical Corp. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NYMXF stock overvalued or undervalued?
Valuation metrics for NYMXF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NYMXF's AI grade for 2026?
Our dual AI analysis gives Nymox Pharmaceutical Corp. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NYMXF's free cash flow?
Nymox Pharmaceutical Corp.'s operating cash flow is N/A, with capital expenditures of N/A.
How does NYMXF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).